Star Imaging and Path Lab Limited has issued a clarification to BSE Limited regarding the recent significant movement in its share price, responding to the exchange's inquiry dated April 09, 2026. The company addressed concerns about price volatility through a formal communication on April 10, 2026.

Regulatory Compliance and Disclosure Status

The company confirmed its adherence to all regulatory disclosure requirements under SEBI LODR Regulations. Star Imaging and Path Lab Limited stated that all material information and events affecting the company's operations and performance have been regularly disclosed to the stock exchange in a timely and accurate manner.

The management emphasized compliance with principles governing disclosures and obligations outlined under Regulation 4 of the SEBI LODR Regulations and relevant circulars issued thereunder.

Price Movement Attribution

Star Imaging and Path Lab Limited clarified that no undisclosed material information or events exist that may influence the price or volume behavior of the company's securities. The company stated that all material facts and information have been properly disclosed and are available in the public domain on BSE Limited's website.

The management attributed the share price movement to market-driven factors, specifically citing general market conditions and speculative activities as the primary drivers. The company emphasized that management has no control over such price movements.

Insider Trading Compliance

The company disclosed that promoters, promoter group members, and key managerial personnel have not dealt in the company's securities in the recent past. This statement addresses potential concerns about insider trading activities that could influence share price behavior.

Commitment to Transparency

Star Imaging and Path Lab Limited reiterated its commitment to comply with SEBI LODR Regulations and assured continued prompt disclosure of any material information or price-sensitive events as required under Regulation 30. The communication was signed by Company Secretary and Compliance Officer Md Shadab Khan, who holds membership number A74659.

Star imaging and path lab Limited has announced the execution of a lease agreement for establishing a new diagnostic and imaging centre in Dwarka, New Delhi, as part of its strategic expansion in the Delhi NCR region. The agreement was executed on April 09, 2026, marking a significant milestone in the company's growth trajectory.

Facility Details and Location

The new diagnostic centre will be established at Plot Number 20, Sector 13, Block-B, Pocket 10, Dwarka, New Delhi, 110075. The facility has been designed to provide comprehensive diagnostic services to cater to the growing healthcare needs in the Dwarka region and surrounding areas.

Investment and Services

The company has committed an approximate capital expenditure of ₹14 crore for setting up this new facility. The centre will offer a comprehensive range of diagnostic services designed to meet diverse medical imaging and pathology requirements.

Services to be offered include:

• MRI (Magnetic Resonance Imaging)
• CT scan services
• Ultrasound imaging
• X-Ray facilities
• Related diagnostic services

Timeline and Operations

The new diagnostic centre is expected to commence operations by August 01, 2026, subject to obtaining necessary regulatory approvals. This timeline allows the company adequate preparation period for equipment installation, staff recruitment, and compliance procedures.

Strategic Impact

This expansion initiative represents the company's commitment to strengthening its presence in the Delhi NCR market. The agreement is structured at arm's length with no related party involvement, ensuring transparency in the transaction. The company expects this new facility to contribute positively to its revenue and operational performance, enhancing its service delivery capabilities in the region.

The disclosure was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's adherence to regulatory requirements and commitment to transparent communication with stakeholders.